SCHEMBL403048

SCHEMBL403048

O=C(O)c1cccc2c(=O)[nH]c(Cc3cccnc3)nc12

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.47
PDE7A Q13946 1/20 0.46
PARP1 P09874 1/20 0.46
PARP2 Q9UGN5 1/20 0.46
USP2 O75604 1/20 0.45
RNASEH1 O60930 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
PDE5A O76074 2/20 0.43
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
CACNA1H O95180 1/20 0.42
POLB P06746 1/20 0.41
PARP14 Q460N5 1/20 0.41
DHODH Q02127 1/20 0.40
PNP P00491 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405606 0.88 KMT2A (0.61) KMT2APARP1PARP2RNASEH1MAPT
SCHEMBL405713 0.81 ALDH1A1 (0.48) ALDH1A1KMT2AUSP2RNASEH1PDE5A
SCHEMBL401142 0.81 PDE5A (0.64) KMT2APARP1PARP2RNASEH1MAPT
SCHEMBL403970 0.79 KDM4C (0.49) PARP1PARP2PDE5A
SCHEMBL404377 0.78 RNASEH1 (0.60) KMT2APARP1PARP2RNASEH1MAPT
SCHEMBL405885 0.78 MAPT (0.47) ALDH1A1KMT2APARP1PARP2RNASEH1
SCHEMBL405915 0.77 PDE5A (0.58) ALDH1A1KMT2APARP1RNASEH1PDE5A
SCHEMBL406541 0.76 PDE5A (0.69) ALDH1A1KMT2APARP1RNASEH1PDE5A
SCHEMBL403861 0.76 RNASEH1 (0.51) ALDH1A1PARP1PARP2RNASEH1KDM4E
SCHEMBL402347 0.75 KDM4E (0.64) PARP1PARP2MAPTPKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
CN-101501007-B Quinazoline derivative ASKA PARMACEUTICAL CO LTD 2014-01-29 CN disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
CN-101557826-A Therapeutic agent for urinary tract disease ASKA PHARM CO LTD (JP) 2009-10-14 CN disclosed
CN-101501007-A Quinazoline derivative ASKA PARMACEUTICAL CO LTD (JP) 2009-08-05 CN disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD ALDH1A1 762/4885KMT2A 2820/4885PDE7A 11/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A ALDH1A1 235/4885KMT2A 3246/4885PDE7A 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.